Telehealth provider eMed announced it has closed a $200 million funding round that values the company at more than $2 billion. The Miami, Florida based startup said the Series A financing was led by Aon Consulting and will be directed toward advancing its agentic AI platform and shoring up finances as it rolls out a new payment model for healthcare designed to reduce employer healthcare spending.
eMed, which has high-profile backing from seven-time Super Bowl champion Tom Brady, positions itself as a partner for employers and government payers to help manage the use of GLP-1 medications. These drugs, used for obesity and diabetes treatment, have prompted significant interest across telehealth providers because their costs have posed obstacles to broader insurance coverage.
The company named several notable investors in the round, including Brady, who also serves as eMed's founding chief wellness officer, the company chief executive Linda Yaccarino, and Jeff Aronin, founder and CEO of Paragon Biosciences, among others, according to eMed.
Established in 2020, eMed found early traction during the COVID-19 pandemic by supplying at-home COVID-19 tests. It later expanded into diagnostics for strep throat and urinary tract infections, but the company has since discontinued those offerings as it refocused its product mix.
On the topic of the financing and the company trajectory, eMed CEO Linda Yaccarino, who previously served as chief executive of social media platform X, told FOX Business Network that the funding validates the company's momentum. Yaccarino said the raise positions eMed as a leading company for population health and as a resource to help employers rein in escalating healthcare costs and alter their cost curves.
The firm and similar telehealth platforms are competing to participate in the rapidly growing GLP-1 weight-loss market, which industry forecasts cited in the original reporting expect to reach substantial annual sales in the coming decade. eMed intends to use the new capital both to enhance its AI-driven capabilities and to support the launch of its healthcare payment approach aimed at lowering employer healthcare expenditures.
Context and next steps
With the fresh capital, eMed is prioritizing technology development and financial stability while it pursues a payment model designed to address employer cost pressures tied to drug coverage. The company will operate in a competitive telehealth landscape focused on GLP-1 management and related population health services.